2017 News

• 12.25.2017
  Information

  CSR page on our website has been updated

• 12.21.2017
  Press Release IR News

  Santen Receives Complete Response Letter from U.S. FDA for Intravitreal Sirolimus (DE-109)

• 11.27.2017
  Press Release IR News

  Santen Files for Manufacturing and Marketing Approval of Glaucoma and Ocular Hypertension Drug Candidate DE-117 (JAN: Omidenepag Isopropyl)

• 11.01.2017
  Press Release IR News

  Santen Announces Approval of Diquas for the Treatment of Dry Eye in China

• 11.01.2017
  Press Release IR News

  Santen Reports the 2nd Quarter Fiscal 2017 Consolidated Performance

• 10.26.2017
  Press Release

  Santen to Participate in UN Global Compact

• 10.04.2017
  Information

  CSR page on our website has been updated

• 09.19.2017
  Press Release IR News

  Santen Selected as a Member of Dow Jones Sustainability Asia Pacific Index, an Index for Socially Responsible Investment

• 09.01.2017
  Press Release IR News

  Notice on Details of Subscription Rights to New Shares(Stock Options for Stock-Linked Remuneration)

• 08.01.2017
  Press Release IR News

  Santen to Grant Subscription Rights to New Shares as Stock Options for Stock-Linked Remuneration

• 08.01.2017
  Press Release IR News

  Santen Reports the 1st Quarter Fiscal 2017 Consolidated Performance

• 07.26.2017
  Press Release IR News

  Santen and TRACON Announce Initiation of a Phase 2a Study of DE-122 for the Treatment of Wet Age-Related Macular Degeneration

• 07.26.2017
  Press Release IR News

  Santen Receives Positive CHMP Opinion in Europe for Ciclosporin eye drops for the Treatment of Paediatric Patients with Severe Vernal Keratoconjunctivitis

• 07.18.2017
  Press Release

  Santen Donates to Northern Kyushu Area Disaster Relief Efforts

• 06.29.2017
  Information

  CSR page on our website has been updated

• 05.10.2017
  Press Release IR News

  Santen Reports Fiscal 2016 Consolidated Performance

• 05.10.2017
  Press Release IR News

  Notice of Board of Director and Corporate Auditor Nominations

• 05.01.2017
  Press Release

  Santen to Establish a Corporate Venture Capital Fund in the United States

• 04.25.2017
  Press Release IR News

  Santen Announces U.S. FDA Filing Acceptance of New Drug Application (NDA) for Intravitreal Sirolimus (DE-109) in the Treatment of NIU-PS

• 04.07.2017
  Press Release IR News

  Santen Announces Strategic Investment in Regenerative Patch Technologies LLC

• 04.05.2017
  Information

  CSR page on our website has been updated

• 03.16.2017
  Press Release IR News

  Santen and Japan Blind Football Association (JBFA) Enter Partnership

• 03.15.2017
  Press Release IR News

  Notice of Corporate Officer Appointments

• 03.02.2017
  Press Release IR News

  SANTEN AND SINGAPORE EYE RESEARCH INSTITUTE (SERI) ANNOUNCE AN EXPANDED RELATIONSHIP INCLUDING THE CREATION OF A NEW JOINT LABORATORY TO DEVELOP NOVEL OPHTHALMIC THERAPEUTICS, DIAGNOSTICS AND DEVICES

• 02.22.2017
  Press Release

  Santen to Cosponsor "Light Up in Green" Campaign during World Glaucoma Week from March 12 to 18, 2017

• 02.09.2017
  Information

  Voice conference on the Financial Result of the 3rd Quarter of FY2016

• 02.07.2017
  Press Release IR News

  Santen Reports the 3rd Quarter Fiscal 2016 Consolidated Performance

• 01.10.2017
  Information

  Presentation materials for the 35th Annual J.P.Morgan Healthcare Conference

News Archive